论文部分内容阅读
目的:为了探讨Ⅱ型呼吸衰竭急性加重期患者血清及的动态变化。sICAM-1IL-12方法:动态观察例Ⅱ型呼吸衰31竭急性加重期患者及例哮喘发作期患者治疗前后血清及变化情况,采用双抗体夹心法测定。20sICAM-1IL-12ELISA结果:Ⅱ型呼吸衰竭急性加重期及哮喘发作期患者治疗前血清水平明显高于健康组,差异有显著性(sICAM-1p<),治疗后均较0.01前有所下降,但均高于正常,变化无显著性。IL-12结论:血清及变化对判断Ⅱ型呼吸衰竭急性加重期患者病情sICAM-1IL-12轻重、估计预后及了解机体免疫病理过程有重要意义。
Objective: To investigate the serum and dynamic changes of type Ⅱ respiratory failure in patients with acute exacerbation. sICAM-1IL-12 Methods: The dynamic observation of type Ⅱ respiratory failure in patients with exacerbation of acute exacerbation of patients and cases of asthma attack patients before and after treatment serum and changes were measured by double antibody sandwich method. The results of 20sICAM-1IL-12 ELISA showed that the level of serum sICAM-1p <0.01 was significantly higher in patients with acute exacerbation of type II respiratory failure and asthma exacerbation than that in healthy group But higher than normal, no significant change. IL-12 Conclusion: Serum and changes in the judgment of type II respiratory failure in patients with acute exacerbations of sICAM-1IL-12 severity, prognosis and understanding of the immune pathological process of great significance.